Grit Biotechnology

Executive Summary

Grit Biotechnology is a preclinical-stage cell therapy company developing next-generation chimeric antigen receptor (CAR) T-cell therapies for solid tumors. Founded in 2020 and based in San Diego, the company has raised $60 million to advance its platform designed to overcome the immunosuppressive tumor microenvironment—a key barrier to CAR-T efficacy in solid cancers. Grit's technology focuses on enhancing T-cell persistence, potency, and safety through proprietary engineering of CAR constructs and co-expression of armoring molecules. The company's lead programs target challenging indications such as ovarian, pancreatic, and lung cancers, aiming to translate preclinical promise into clinical benefit. With a strong scientific foundation and a growing team, Grit is positioned to address an unmet need in oncology, though it remains early-stage with no clinical data yet. Success will depend on execution of preclinical studies, regulatory filings, and eventual Phase 1 trial results. The company's approach represents a meaningful step forward in cellular immunotherapy, with potential to expand the reach of CAR-T beyond hematologic malignancies.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data in solid tumor models40% success
• Q1 2027IND submission for lead CAR-T candidate30% success
• Q2 2027Strategic partnership or licensing deal for technology platform20% success